<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="561">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140867</url>
  </required_header>
  <id_info>
    <org_study_id>E2090-S082-409</org_study_id>
    <nct_id>NCT01140867</nct_id>
  </id_info>
  <brief_title>Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy</brief_title>
  <official_title>A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>KFDA: Korea</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of this study is to assess the efficacy and safety of zonisamide as adjunctive
      therapy in patients with uncontrolled partial epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The object of this study is to assess the efficacy and safety of zonisamide as adjunctive
      therapy in patients with uncontrolled partial epilepsy. Subject takes zonisamide for 16
      weeks (4 weeks-titration period, 8 weeks maintenance period). Dose range of zonisamide is
      100 ~ 400 mg/day and target dose is 300 mg/day. After 16 weeks, zonisamide efficacy is
      measured by seizure reduction rate (Each type of seizure: simple partial seizures [SPS],
      complex partial seizures [CPS], simple partial seizures evolving into generalized
      tonic-clonic convulsions [SGTC] and total seizure frequency), seizure free rate, responder
      rate, quality of life in epilepsy (QOLIE-31) and investigator's global evaluation scale.
      Safety of zonisamide in this study will be estimated by adverse event profile, retention
      rate and dose of exposure. The duration of this clinical study is 2 years including period
      of subject enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Seizure Reduction Rate</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of the seizure reduction after Zonisamide treatment comparing baseline seizure frequency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure Free Rate</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of the participants who experienced no seizure during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants whose median percentage change in seizure frequency after Zonisamide treatment is reduced over 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL-QOLIE31 (Quality of Life in Epilepsy)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life assessment tool. Overall scores is calculated by summing subsections, and it ranges from 0 to 100. Higher score presents higher quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zonisamide</intervention_name>
    <description>zonisamide 100 mg tablet</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Epilepsy patient over 15 years old who agrees with Informed Consent Form

          2. Patient who has classifiable uncontrolled partial epilepsy according to International
             Classification of Epileptic Seizures.

          3. Patient who has 3 ~ dozens of partial seizure (average more than once seizure per 4
             weeks) last 12 weeks despite taking 1 ~ 3 antiepileptic drug(s).

          4. Patient who takes 1 ~ 3 marketed antiepileptic drug(s) excluding zonisamide at point
             of enrollment time.

          5. Before study visit, patient who takes stable dose of antiepileptic drug more than 4
             weeks.

        Exclusion criteria:

          1. Patient who has progressive central nervous system (CNS) disorder and/or degenerative
             disease of the brain.

          2. Patient who experiences pseudoseizures and/or who has uncountable clusters.

          3. Patient who has serious systemic or drug metabolism affecting disorder .

          4. Upward of doubled normal glutamic oxaloacetic transaminase (GOT), glutamic pyruvic
             transaminase (GPT), bilirubin, blood urea nitrogen (BUN), creatinine levels.

          5. Patient who has absolute neutrophil counts &lt;1800/mm3 or platelets &lt;100,000/mm3.

          6. Patient who has medical history of renal stones.

          7. Patient who is allergic to sulfonamide.

          8. Medical history of medicinal poisoning and/or alcoholism and/or serious psychological
             disorder.

          9. Pregnant women, lactating women, women of childbearing age who do not use a
             preventive method of conception.

         10. A terminal patient and/or a scheduled surgical patient.

         11. Patient who has medication history of zonisamide.

         12. Patient who participated other clinical trial within the last 12 weeks at point of
             enrollment time of this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihee Mun</last_name>
    <role>Study Director</role>
    <affiliation>Medical Department, Eisai Korea Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dong-A University Hospital, Dept. of Neurology</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje Univ. Pusan Paik Hospital, Dept. of Neurology</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung Univ.Dongsan Medical Centre, Dept. of Neurology</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook Natl. Univ. Hosp., Dept. of Neurology</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam Univ. Medical Center, Dept. of Neurology</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon Medical School Gil Medical Centre, Dept.of Neurology</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natl. Health Insurance Corporation Ilsan Hosp., Dept. of Neurology</name>
      <address>
        <city>Koyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang CHA Hospital, Dept. of Neurology</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hosp., Dept. of Neurology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Dept. of Neurology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <lastchanged_date>September 8, 2011</lastchanged_date>
  <firstreceived_date>May 19, 2010</firstreceived_date>
  <firstreceived_results_date>August 5, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Partial</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was recruited at 10 centers in Korea during the period of February 2008 to August 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zonisamide</title>
          <description>Initial dose was 100mg/day, increased by 100mg in week 2 and 4. The target dose was 300mg/day, and the maximum dose was 400mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uncooperative patient</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zonisamide</title>
          <description>Initial dose was 100mg/day, increased by 100mg in week 2 and 4. The target dose was 300mg/day, and the maximum dose was 400mg/day.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="121"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.70" spread="11.19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="121"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seizure Reduction Rate</title>
        <description>The percentage of the seizure reduction after Zonisamide treatment comparing baseline seizure frequency.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy analyses were based on the FAS (Full analysis set) population, which was comprised of all patients who administrated Zonisamide at least once and reached the maintenance period to evaluate the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide</title>
            <description>Initial dose was 100mg/day, increased by 100mg in week 2 and 4. The target dose was 300mg/day, and the maximum dose was 400mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seizure Reduction Rate</title>
            <description>The percentage of the seizure reduction after Zonisamide treatment comparing baseline seizure frequency.</description>
            <units>Percentage of Seizure Reduction Rate</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-16.35" spread="436"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure Free Rate</title>
        <description>The percentage of the participants who experienced no seizure during the trial.</description>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy analyses were based on the FAS (Full analysis set) population, which was comprised of all patients who administrated Zonisamide at least once and reached the maintenance period to evaluate the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide</title>
            <description>Initial dose was 100mg/day, increased by 100mg in week 2 and 4. The target dose was 300mg/day, and the maximum dose was 400mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seizure Free Rate</title>
            <description>The percentage of the participants who experienced no seizure during the trial.</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24.51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate</title>
        <description>The percentage of participants whose median percentage change in seizure frequency after Zonisamide treatment is reduced over 50%.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy analyses were based on the FAS (Full analysis set) population, which was comprised of all patients who administrated Zonisamide at least once and reached the maintenance period to evaluate the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide</title>
            <description>Initial dose was 100mg/day, increased by 100mg in week 2 and 4. The target dose was 300mg/day, and the maximum dose was 400mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Responder Rate</title>
            <description>The percentage of participants whose median percentage change in seizure frequency after Zonisamide treatment is reduced over 50%.</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61.76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL-QOLIE31 (Quality of Life in Epilepsy)</title>
        <description>Quality of life assessment tool. Overall scores is calculated by summing subsections, and it ranges from 0 to 100. Higher score presents higher quality of life.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy analyses were based on the FAS (Full analysis set) population, which was comprised of all patients who administrated Zonisamide at least once and reached the maintenance period to evaluate the primary endpoint. Regarding QOLIE-31, among FAS population, the patients who have both of baseline and 16 week evaluation are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide</title>
            <description>Initial dose was 100mg/day, increased by 100mg in week 2 and 4. The target dose was 300mg/day, and the maximum dose was 400mg/day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>QoL-QOLIE31 (Quality of Life in Epilepsy)</title>
            <description>Quality of life assessment tool. Overall scores is calculated by summing subsections, and it ranges from 0 to 100. Higher score presents higher quality of life.</description>
            <units>Units on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline- Pre-QOLIE 31 total score (N=90)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.67" spread="15.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>16 weeks - Post- QOLIE 31 total score (N=90)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57.70" spread="15.74"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zonisamide</title>
          <description>Initial dose was 100mg/day, increased by 100mg in week 2 and 4. The target dose was 300mg/day, and the maximum dose was 400mg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jihee Mun, Pharmacist, Medical Department manager</name_or_title>
      <organization>Eisai Korea Inc.</organization>
      <phone>+82-2-3451-5531</phone>
      <email>jihee_mun@eisaikorea.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
